Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry
Bjorn Gudbjornsson,1,2 Arni Jon Geirsson,3,4 Niels Steen Krogh5 1Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland; 2Faculty of Medicine, University of Iceland, Reykjavik, Iceland; 3Department of Rheumatology, University Hospital, Reykjavik, Iceland; 4Laeknasetrid - Medical C...
Published in: | Psoriasis: Targets and Therapy |
---|---|
Main Authors: | , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Dove Press
2018
|
Subjects: | |
Online Access: | https://www.dovepress.com/low-starting-dosage-of-infliximab-with-possible-escalating-dosage-in-p-peer-reviewed-fulltext-article-PTT |
id |
ftdovepress:oai:dovepress.com/38147 |
---|---|
record_format |
openpolar |
spelling |
ftdovepress:oai:dovepress.com/38147 2023-05-15T16:45:39+02:00 Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry Gudbjornsson,Bjorn Geirsson,Arni Jon Krogh,Niels Steen 2018-05-04 text/html https://www.dovepress.com/low-starting-dosage-of-infliximab-with-possible-escalating-dosage-in-p-peer-reviewed-fulltext-article-PTT en eng Dove Press info:eu-repo/semantics/altIdentifier/doi/10.2147/PTT.S161522 https://www.dovepress.com/low-starting-dosage-of-infliximab-with-possible-escalating-dosage-in-p-peer-reviewed-fulltext-article-PTT info:eu-repo/semantics/openAccess Psoriasis: Targets and Therapy Original Research info:eu-repo/semantics/article 2018 ftdovepress https://doi.org/10.2147/PTT.S161522 2022-12-27T22:22:04Z Bjorn Gudbjornsson,1,2 Arni Jon Geirsson,3,4 Niels Steen Krogh5 1Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland; 2Faculty of Medicine, University of Iceland, Reykjavik, Iceland; 3Department of Rheumatology, University Hospital, Reykjavik, Iceland; 4Laeknasetrid - Medical Clinic, University of Iceland, Reykjavik, Iceland; 5Zitelab Aps, Copenhagen, Denmark Objective: To explore differences in response to a low dosage regimen of infliximab with an escalating dosage in comparison to a standard dosage of etanercept and adalimumab in patients with psoriatic arthritis (PsA). Methods: Biologically naïve PsA patients who were beginning anti-TNF-α therapy were selected from the ICEBIO registry. Demographics and clinical differences were compared in four treatment groups: infliximab <4 mg/kg; infliximab >4 mg/kg; etanercept or adalimumab at baseline and on follow-up (6 and 12 months, last visit). The Kruskal–Wallis rank sum test was used for comparison of the groups and the Wilcoxon test to compare the two infliximab dosage regimens. Results: One hundred and eighty-five patients (61% female) were identified; 84 patients received infliximab, 66 etanercept, and 35 adalimumab. A total of 19% of the patients treated with infliximab escalated their dosage ≥4 mg/kg. No significant differences were observed at baseline in respect to visual analog scale (VAS) pain, VAS fatigue, Health Assessment Questionnaire, C-reactive protein (CRP), numbers of swollen or tender joints, or Disease Activity Score (DAS) 28-CRP values. A similar treatment response was observed in all four treatment groups on follow-up. Conclusion: In respect to treatment effects, a low dosage of infliximab with possible escalating dosage is acceptable for the majority of PsA patients who are in need of biological treatment. Keywords: psoriatic arthritis, outcome, biological treatment, routine care, clinical nationwide registry Article in Journal/Newspaper Iceland Dove Medical Press Steen ENVELOPE(7.780,7.780,62.571,62.571) Psoriasis: Targets and Therapy Volume 8 13 19 |
institution |
Open Polar |
collection |
Dove Medical Press |
op_collection_id |
ftdovepress |
language |
English |
topic |
Psoriasis: Targets and Therapy |
spellingShingle |
Psoriasis: Targets and Therapy Gudbjornsson,Bjorn Geirsson,Arni Jon Krogh,Niels Steen Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry |
topic_facet |
Psoriasis: Targets and Therapy |
description |
Bjorn Gudbjornsson,1,2 Arni Jon Geirsson,3,4 Niels Steen Krogh5 1Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland; 2Faculty of Medicine, University of Iceland, Reykjavik, Iceland; 3Department of Rheumatology, University Hospital, Reykjavik, Iceland; 4Laeknasetrid - Medical Clinic, University of Iceland, Reykjavik, Iceland; 5Zitelab Aps, Copenhagen, Denmark Objective: To explore differences in response to a low dosage regimen of infliximab with an escalating dosage in comparison to a standard dosage of etanercept and adalimumab in patients with psoriatic arthritis (PsA). Methods: Biologically naïve PsA patients who were beginning anti-TNF-α therapy were selected from the ICEBIO registry. Demographics and clinical differences were compared in four treatment groups: infliximab <4 mg/kg; infliximab >4 mg/kg; etanercept or adalimumab at baseline and on follow-up (6 and 12 months, last visit). The Kruskal–Wallis rank sum test was used for comparison of the groups and the Wilcoxon test to compare the two infliximab dosage regimens. Results: One hundred and eighty-five patients (61% female) were identified; 84 patients received infliximab, 66 etanercept, and 35 adalimumab. A total of 19% of the patients treated with infliximab escalated their dosage ≥4 mg/kg. No significant differences were observed at baseline in respect to visual analog scale (VAS) pain, VAS fatigue, Health Assessment Questionnaire, C-reactive protein (CRP), numbers of swollen or tender joints, or Disease Activity Score (DAS) 28-CRP values. A similar treatment response was observed in all four treatment groups on follow-up. Conclusion: In respect to treatment effects, a low dosage of infliximab with possible escalating dosage is acceptable for the majority of PsA patients who are in need of biological treatment. Keywords: psoriatic arthritis, outcome, biological treatment, routine care, clinical nationwide registry |
format |
Article in Journal/Newspaper |
author |
Gudbjornsson,Bjorn Geirsson,Arni Jon Krogh,Niels Steen |
author_facet |
Gudbjornsson,Bjorn Geirsson,Arni Jon Krogh,Niels Steen |
author_sort |
Gudbjornsson,Bjorn |
title |
Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry |
title_short |
Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry |
title_full |
Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry |
title_fullStr |
Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry |
title_full_unstemmed |
Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry |
title_sort |
low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide icelandic icebio registry |
publisher |
Dove Press |
publishDate |
2018 |
url |
https://www.dovepress.com/low-starting-dosage-of-infliximab-with-possible-escalating-dosage-in-p-peer-reviewed-fulltext-article-PTT |
long_lat |
ENVELOPE(7.780,7.780,62.571,62.571) |
geographic |
Steen |
geographic_facet |
Steen |
genre |
Iceland |
genre_facet |
Iceland |
op_relation |
info:eu-repo/semantics/altIdentifier/doi/10.2147/PTT.S161522 https://www.dovepress.com/low-starting-dosage-of-infliximab-with-possible-escalating-dosage-in-p-peer-reviewed-fulltext-article-PTT |
op_rights |
info:eu-repo/semantics/openAccess |
op_doi |
https://doi.org/10.2147/PTT.S161522 |
container_title |
Psoriasis: Targets and Therapy |
container_volume |
Volume 8 |
container_start_page |
13 |
op_container_end_page |
19 |
_version_ |
1766035804366307328 |